Adverse effects of androgen-deprivation therapy in prostate cancer and their management

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

(2015) Manfred Wirth et al.   EUROPEAN UROLOGY

Avoiding obsolescence in advanced prostate cancer management: a guide for urologists

(2014) Neal D. Shore et al.   BJU INTERNATIONAL

The Challenges of Managing Urological Malignancy in the Elderly

(2014) Yasmin Abu-Ghanem et al.   BJU INTERNATIONAL

Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?

(2014) Johannes M. Wolff et al.   BJU INTERNATIONAL

Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial

(2014) Prue Cormie et al.   BJU INTERNATIONAL

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

(2014) Dana E. Rathkopf et al.   EUROPEAN UROLOGY

Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer

(2014) Giorgio Gandaglia et al.   EUROPEAN UROLOGY

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study

(2014) Bertrand Tombal et al.   LANCET ONCOLOGY

Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer

(2014) Grace L. Lu-Yao et al.   JAMA Internal Medicine

Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects

(2013) Lauren M. Walker et al.   Clinical Genitourinary Cancer

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2013) Axel Heidenreich et al.   EUROPEAN UROLOGY

Androgen-deprivation Therapy and Diabetes Control Among Diabetic Men with Prostate Cancer

(2013) Nancy L. Keating et al.   EUROPEAN UROLOGY

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up

(2013) Urs E. Studer et al.   EUROPEAN UROLOGY

Androgen-deprivation Therapy and Cardiovascular Harm: Let's Not Throw Out the Baby with the Bathwater

(2013) Paul L. Nguyen   EUROPEAN UROLOGY

Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study

(2013) Christina G. Jespersen et al.   EUROPEAN UROLOGY

A Multicentre Year-long Randomised Controlled Trial of Exercise Training Targeting Physical Functioning in Men with Prostate Cancer Previously Treated with Androgen Suppression and Radiation from TROG 03.04 RADAR

(2013) Daniel A. Galvão et al.   EUROPEAN UROLOGY

Androgen Deprivation Therapy and Risk of Acute Kidney Injury in Patients With Prostate Cancer

(2013) Francesco Lapi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

(2013) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review

(2013) Jason R. Gardner et al.   JOURNAL OF CLINICAL ONCOLOGY

775 THE AUSTRALIAN EXPERIENCE OF THE ‘MAN PLAN' EXERCISE PROGRAM FOR PATIENTS WITH PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY

(2013) Lawrence Kim et al.   JOURNAL OF UROLOGY

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

(2013) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osteoporosis Management Program Decreases Incidence of Hip Fracture in Patients With Prostate Cancer Receiving Androgen Deprivation Therapy

(2013) Ali-Asghar Zhumkhawala et al.   UROLOGY

Efficacy of Intermittent Androgen Deprivation Therapy vs Conventional Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Meta-analysis

(2013) Huei-Ting Tsai et al.   UROLOGY

Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines

(2013) A. S. Cheung et al.   Andrology

A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study

(2012) Laurence H. Klotz et al.   EUROPEAN UROLOGY

Does Comorbidity Influence the Risk of Myocardial Infarction or Diabetes During Androgen-Deprivation Therapy for Prostate Cancer?

(2012) Nancy L. Keating et al.   EUROPEAN UROLOGY

Prevention of Gynecomastia and Breast Pain Caused by Androgen Deprivation Therapy in Prostate Cancer: Tamoxifen or Radiotherapy?

(2012) Gustavo Arruda Viani et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

(2012) Juanita M. Crook et al.   NEW ENGLAND JOURNAL OF MEDICINE

Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer

(2011) Vincenzo Pagliarulo et al.   EUROPEAN UROLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States

(2011) Jennifer L. Beebe-Dimmer et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

(2011) A Serpa Neto et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

(2010) Glenn N. Levine et al.   CIRCULATION

Structural Decay of Bone Microarchitecture in Men with Prostate Cancer Treated with Androgen Deprivation Therapy

(2010) E. J. Hamilton et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life

(2010) Stacy Elliott et al.   Journal of Sexual Medicine

Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management

(2010) Howard S Kim et al.   Current Opinion in Supportive and Palliative Care

Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values

(2009) Vivek K. Wadhwa et al.   BJU INTERNATIONAL

The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer

(2009) Yu-Ning Wong et al.   EUROPEAN UROLOGY

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial

(2009) Jacques Irani et al.   LANCET ONCOLOGY

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE